8-K current report · filed Oct 13, 2026

Mirum Pharmaceuticals, Inc. (MIRM) 8-K Current Report: October 13, 2026

Item 8.01MIRM overview

Short answer

Mirum Pharmaceuticals, Inc. (MIRM) filed an 8-K current report with the SEC on October 13, 2026 reporting Item 8.01 (Other Events). Phase 3 EXPAND met its primary endpoint and all five prespecified secondary endpoints, strengthening LIVMARLI’s expansion case.

Mirum Pharmaceuticals, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 8.01 · Other Events

  • Phase 3 EXPAND met its primary endpoint and all five prespecified secondary endpoints, strengthening LIVMARLI’s expansion case
  • Pediatric pruritus improved 0.98 points versus placebo, p=0.0004, with serum bile acids falling 69.0% versus placebo, p<0.0001
  • Biliary atresia patients with native livers showed a 1.15-point pruritus treatment effect and 73.1% serum bile acid treatment effect
  • Safety was broadly comparable, but diarrhea occurred in 64.0% of LIVMARLI patients versus 11.1% on placebo
  • Supplemental U.S. New Drug Application planned for the first half of 2027, creating a regulatory catalyst and potential market expansion

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Mirum Pharmaceuticals, Inc. 8-K filings

Get the next MIRM 8-K as it lands

Follow MIRM for push alerts, or ask the research agent what this filing means.